Claritev Appoints Jennifer Main to Board of Directors
The healthcare company added a new directorship to the board to leverage Main's extensive financial and public sector experience.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you believe corporate boards benefit from adding members with experience in government and public policy?
Claritev has appointed Jennifer Main to its Board of Directors to help guide the firm's growth strategy. The company created a new directorship to accommodate the appointment, which officially took effect on October 15, 2026.
Why it matters
By recruiting Main, Claritev aims to utilize her deep expertise in public sector healthcare and financial leadership. The board intends for her background to bolster the company's long-term corporate growth and strategic goals.
Claritev currently serves 60 million consumers and 1.4 million contracted providers. The company's reach also includes 750 healthcare payers and 100,000 employers.
The players
Jennifer Main
She is the newly appointed member of the Claritev Board of Directors who previously held high-level financial and operational roles in both the public and private health sectors.
Claritev
This McLean-based company provides services to a massive network of healthcare payers, employers, and providers.
Centers for Medicare & Medicaid Services
This federal agency administers the nation's major healthcare programs, including Medicare and Medicaid.
The details
Main currently serves as the Chief Financial Officer for both RealMDai and Overture Life. Her extensive background includes serving as CFO and COO of Amalgam Rx from 2021 to 2026 and as COO of the Centers for Medicare & Medicaid Services between 2018 and 2021.
Timeline
Jennifer Main joined the Claritev Board of Directors on October 15, 2026.
Main served as the COO of the Centers for Medicare & Medicaid Services from 2018 to 2021.
Main worked as the CFO and COO of Amalgam Rx from 2021 to 2026.
Main assumed the role of CFO for RealMDai and Overture Life in March 2026.
The Troubled Assets Relief Program, where Main once served as CFO, began in 2008.
Market Landscape
Main's appointment reflects a broader trend of private healthcare firms recruiting high-level public sector experts to navigate complex regulatory environments. This move positions Claritev to better compete by leveraging experience similar to that gained during the implementation of the Troubled Assets Relief Program.
For the average client or partner of Claritev, this board appointment signals a potential shift in the firm's future service offerings or strategic direction. The company currently supports 1.4 million providers, who may see impacts as the firm integrates new leadership expertise into its core operations.
The takeaway
Board appointments at major healthcare companies often provide a roadmap for future corporate strategy and expansion priorities. Investors and clients should monitor subsequent announcements from the company regarding how Main's public sector background influences their new service development.
Further reading
For more on the industry's leadership shifts, visit our Healthcare section.
Live Poll
Do you believe corporate boards benefit from adding members with experience in government and public policy?
